New contrast agent may sharpen pituitary tumor detection
NCT ID NCT06846853
First seen May 15, 2026 · Last updated May 15, 2026
Summary
This study tests whether a newer FDA-approved contrast agent, Gadopiclenol, provides clearer images of pituitary lesions on MRI compared to the standard agent, Gadobutrol. Ten adults with known or suspected pituitary lesions will receive both agents in random order, with neither the participant nor the researcher knowing which is used. The goal is to see if Gadopiclenol improves diagnostic image quality.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONTRAST ENHANCED IMAGES VS. NON-CONTRAST IMAGES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Connecticut Health Center
RECRUITINGFarmington, Connecticut, 06030, United States
Conditions
Explore the condition pages connected to this study.